Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

Efficacy and safety of regdanvimab in patients with mild to moderate COVID-19: A rapid review and meta-analysis

Tue Apr 16 04:53:50 2024

(2023) Efficacy and safety of regdanvimab in patients with mild to moderate COVID-19: A rapid review and meta-analysis. British Journal of Clinical Pharmacology. pp. 1282-1290. ISSN 0306-5251

Full text not available from this repository.

Official URL: <Go to ISI>://WOS:000930659900001


AimsThis study aimed to evaluate the efficacy and safety of regdanvimab, an anti-SARS-COV-2 monoclonal antibody approved by the European Medicines Agency in November 2021, for the treatment of confirmed COVID-19 disease. MethodsCochrane Library, PubMed, medRxiv and Google Scholar were searched for relevant evidence up to October 27, 2022. The quality of included studies was assessed using the Cochrane risk of bias tools. Data were analysed using RevMan software. ResultsEight studies involving 4793 patients were included. A significant difference was observed between the regdanvimab and no-regdanvimab groups in terms of length of hospital stay (mean difference MD = -1.15, 95% confidence interval CI: -1.80 to -0.43), clinical recovery (odds ratio OR = 2.09, 95% CI: 1.38 to 3.18), disease progression (OR = 0.23, 95% CI: 0.16 to 0.33), the need for oxygen therapy (OR = 0.33, 95% CI: 0.25 to 0.43) and duration of oxygen therapy (MD = -3.00, 95% CI: -4.44 to -1.56). However, no significant difference was detected between 2 groups regarding mortality rate (OR = 0.46, 95% CI: 0.11 to 1.89), need for mechanical ventilation (OR = 0.39, 95% CI: 0.08 to 1.89) and hospital admission rate (OR = 0.61, 95% CI: 0.35 to 1.03). The incidence of adverse events was similar in both groups (OR = 0.96, 95% CI: 0.77 to 1.18). ConclusionRegdanvimab was not effective in reducing mortality and hospital admission rate in patients with mild to moderate COVID-19, but it was effective in improving other efficacy outcomes. Further research is needed to confirm these findings.

Item Type: Article
Keywords: COVID-19 monoclonal antibody regdanvimab SARS-COV-2 Pharmacology & Pharmacy
Page Range: pp. 1282-1290
Journal or Publication Title: British Journal of Clinical Pharmacology
Journal Index: ISI
Volume: 89
Number: 4
Identification Number:
ISSN: 0306-5251
Depositing User: مهندس مهدی شریفی

Actions (login required)

View Item View Item